| Literature DB >> 31058164 |
Abstract
Introduction: Therapeutic management of primary obstructive megaureter (POM) requiring surgery has been under debate for the last 15 years especially regarding the outcomes of endoscopic techniques compared to most traditional approaches. This review aims to analyze endoscopic High-Pressure Balloon Dilatation (HPBD) using the IDEAL model, a five-stage framework that describes surgical innovations (Idea, Development, Exploration, Assessment, and Long-term Study) and provides recommendations for a rigorous stepwise surgical research pathway. This model has been developed and demonstrated its value in evaluating surgical innovations assessing data quality and providing relevant information for the optimal design and feasibility of research in surgery. Materials andEntities:
Keywords: CAKUT (congenital anomalies of the kidney and urinary tract); clinical outcome assessment (COA); endourologic treatment; evidence–based medicine; megaureter; minimally invasive surgery (MIS); research in surgery
Year: 2019 PMID: 31058164 PMCID: PMC6478015 DOI: 10.3389/fsurg.2019.00020
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
IDEAL reported cohorts assessment.
| 2a and 2b | Endoscopic balloon dilatation in primary obstructive megaureter: Long-term results ( | Retrospective | Short and long-term outcomes. Technique has reached stability and consensus | Eligibility + | No | Adequate cohort description + |
| 2a and 2b | High pressure balloon dilatation of the ureterovesical junction in primary obstructive megaureter: Infectious morbidity ( | Retrospective | Safety of the procedure. | Eligibility − | Yes | Adequate cohort description + |
| 2b | Postoperative vesicoureteral reflux after high-pressure balloon dilation of the ureterovesical junction in primary obstructive megaureter. Incidence, management, and predisposing factors ( | Retrospective | Medium and long-term complications. Technnique has reached stability and consensus | Eligibility − | No | Adequate cohort description + |
| 2b | Can endoscopic balloon dilation for primary obstructive megaureter be effective in a long-term follow-up? ( | Retrospective | Long-term outcomes | Eligibility + (non-specific data) | No | Adequate cohort description + |
| 2b | Primary obstructive megaureter in infants: our experience with endoscopic balloon dilation and cutting balloon ureterotomy ( | Retrospective/prospective? | Eligibility + (non-specific data) | No | Adequate cohort description + | |
| 2a and 2b | Primary Obstructive Megaureter: The Role of High Pressure Balloon Dilation ( | Retrospective | Safety of the procedure | Eligibility − | Adequate cohort description + | |
| 2a and 2b | Endoscopic management and the role of double stenting for primary obstructive megaureters ( | Retrospective/prospective? | Safety of the procedure | Eligibility − | Yes | Adequate cohort description + |
POM, Primary obstructive megaureter; FU, Follow up; HPBD, High pressure balloon dilatation.
Cohorts reported clinical outcomes.
| Endoscopic balloon dilatation in primary obstructive megaureter: Long-term results ( | 121 POM | Distal ureter > 25 mm excluded from HPBD | No | Median 10.3 years (4.7–12.2 years) | Jj stent migration-replacement ( | 12/12 |
| High pressure balloon dilatation of the ureterovesical junction in primary obstructive megaureter: Infectious morbidity ( | 12 patients/12 ureters | No | Mean 26.5 months (20–44 months) | Redilation ( | 9/12 | |
| Postoperative vesicoureteral reflux after high-pressure balloon dilation of the ureterovesical junction in primary obstructive megaureter. Incidence, management and predisposing factors ( | 20 patients/22 ureters | VCUG routinely performed as FU protocol | No | Ureteric reimplantation | 17/22 | |
| Can endoscopic balloon dilation for primary obstructive megaureter be effective in a long-term follow-up? ( | 19 patients/20 ureters | JJ stent insertion using an ureteral bridge | No | Mean 6.9 years (3.9–13.3 years) | DFR stable | 19/20 |
| Primary obstructive megaureter in infants: our experience with endoscopic balloon dilation and cutting balloon ureterotomy ( | HPBD 7 patients/10 ureters | Technique based on intraoperative findings: | No | Mean 21 months (2–44 months) | HPBD decrease ureterohydronephrosis 7/7 | 5/7 |
| Primary Obstructive Megaureter: the Role of High Pressure Balloon Dilation ( | 29 patients/32 ureters | Dilating catheter change (>5 mm) | Yes | Median 47 (IQR 39,07) months | Re-dilation | 26/29 |
| Endoscopic management and the role of double stenting for primary obstructive megaureters ( | HPBD 12 cases | Exclusion “narrow segment” > 3 cm | No | Mean of 3.2 years | DRF (MRU) stable 12/12 | 12/12 |
| Total cohorts | HPBD 114 units | 4 | 2 months−13.3 years | 100/114 |
POM, Primary obstructive megaureter; FU, Follow up; VCUG, Voiding cystourethrogram; FU, Follow up; HPBD, High pressure balloon dilatation; CBD, Cutting balloon dilatation; DRF, Differential renal function; UTI, Urinary tract infection; VUR, Vesicoureteric reflux.